Evidence map›Paper›PMID 31834910›Full record

ArticlePloS one2019

An investigation of machine learning methods in delta-radiomics feature analysis.

Yushi Chang, Kyle Lafata, Wenzheng Sun, Chunhao Wang, Zheng Chang, John P Kirkpatrick, Fang-Fang Yin

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.

  1. Delta radiomics: a systematic review.La Radiologia medica · 2021
    Pooled it
  2. Trial
  3. Article
  4. Article
  5. Radiomics in spinal research: a narrative review.Frontiers in bioengineering and biotechnology · 2026
    Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Yushi ChangMedical Physics Graduate Program, Duke University, Durham, North Carolina, United States of America.ORCID 0000-0001-6566-0796
Kyle LafataDepartment of Radiation Oncology, Duke University Medical Center, Durham, North Carolina, United States of America.
Wenzheng SunSchool of Information Science and Engineering, Shandong University, Qingdao, Shandong, Shandong, People's Republic of China.
Chunhao WangDepartment of Radiation Oncology, Duke University Medical Center, Durham, North Carolina, United States of America.
Zheng ChangDepartment of Radiation Oncology, Duke University Medical Center, Durham, North Carolina, United States of America.
John P KirkpatrickDepartment of Radiation Oncology, Duke University Medical Center, Durham, North Carolina, United States of America.
Fang-Fang YinDepartment of Radiation Oncology, Duke University Medical Center, Durham, North Carolina, United States of America.
Duke Medical Center · USDuke University · USShandong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThis study aimed to investigate the effectiveness of using delta-radiomics to predict overall survival (OS) for patients with recurrent malignant gliomas treated by concurrent stereotactic radiosurgery and bevacizumab, and to investigate the effectiveness of machine learning methods for delta-radiomics feature selection and building classification models.

methodsThe pre-treatment, one-week post-treatment, and two-month post-treatment T1 and T2 fluid-attenuated inversion recovery (FLAIR) MRI were acquired. 61 radiomic features (intensity histogram-based, morphological, and texture features) were extracted from the gross tumor volume in each image. Delta-radiomics were calculated between the pre-treatment and post-treatment features. Univariate Cox regression and 3 multivariate machine learning methods (L1-regularized logistic regression [L1-LR], random forest [RF] or neural networks [NN]) were used to select a reduced number of features, and 7 machine learning methods (L1-LR, L2-LR, RF, NN, kernel support vector machine [KSVM], linear support vector machine [LSVM], or naïve bayes [NB]) was used to build classification models for predicting OS. The performances of the total 21 model combinations built based on single-time-point radiomics (pre-treatment, one-week post-treatment, and two-month post-treatment) and delta-radiomics were evaluated by the area under the receiver operating characteristic curve (AUC).

resultsFor a small cohort of 12 patients, delta-radiomics resulted in significantly higher AUC than pre-treatment radiomics (p-value<0.01). One-week/two-month delta-features resulted in significantly higher AUC (p-value<0.01) than the one-week/two-month post-treatment features, respectively. 18/21 model combinations were with higher AUC from one-week delta-features than two-month delta-features. With one-week delta-features, RF feature selector + KSVM classifier and RF feature selector + NN classifier showed the highest AUC of 0.889.

conclusionsThe results indicated that delta-features could potentially provide better treatment assessment than single-time-point features. The treatment assessment is substantially affected by the time point for computing the delta-features and the combination of machine learning methods for feature selection and classification.

Indexed as

AlgorithmsMachine LearningGliomaHumansImage Interpretation, Computer-AssistedMagnetic Resonance ImagingNeoplasm Recurrence, LocalRadiosurgeryROC Curve

Identifiers

PMID31834910
PMCPMC6910670
OpenAlexW2903828121

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.